Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-α therapy

Journal of Medical Virology

Volumn 65, Issue 3, 2001, Pages 510-516

  Kimball, Pam ^a   Elswick, R K ^a   Shiffman, Mitchell ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Cytokines; Hepatitis C; IFN resistance

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ETHNIC GROUP; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MALE; NEGRO; RACE DIFFERENCE; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIVIRAL AGENTS; CYTOKINES; DRUG RESISTANCE, VIRAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 0034788060     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2065     Document Type: Article

References (39)

1. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: Results of a randomized multicenter trial
2. Ethnic and sex differences in the total and differential white cell count and platelet count
3. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors
4. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor
5. The mechanism of chronicity in hepatitis C virus infection
6. Mutations in the NS5A region do not predict interferon responsiveness in American patients infected with genotype lb hepatitis C virus
7. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter, randomized, controlled trial
8. Tumor necrosis factor genetic polymorphisms correlate with infections after liver transplantation
9. Hepatitis C is a poor prognostic indicator in black kidney transplant recipients
10. The antiviral compound ribavirin modulates the T helper Th1/Th2 subset balance in hepatitis B and C virus specific immune responses
11. Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon
12. Stronger immune responsiveness of blacks versus whites may account for renal allograft survival differences
13. The paradox of cytokine monitoring: Predictors of immunologic activity as well as immunologic silence following cardiac transplantation
14. Cytokines in viral hepatitis
15. Tumor necrosis factor a gene expression and the response to interferon in chronic hepatitis C
16. 10 Year follow-up after interferon alpha therapy for chronic hepatitis C
17. Pathogenesis, natural history, treatment and prevention of hepatitis C
18. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
19. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer
20. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients
21. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C
22. The impact of race and HLA matching on long term survival following cardiac transplantation
23. Interferon resistance of hepatitis C virus genotype 1b: Relationship to nonstructural 5A gene quasispecies mutations
24. A randomized trial of ribavirin and interferon a vs interferon alone in patients with chronic hepatitis C who were non-responders to a previous treatment
25. Randomized trial of IFNa2b plus ribavirin for 48 wks or 24 wks versus IFNa2b plus placebo for 48 wks for treatment of chronic infection with hepatitis C virus
26. Racial differences in responses to therapy with interferon in chronic hepatitis C
27. Randomized, double blind, placebo controlled trial on interferon alpha 2b with and without ribavirin for chronic hepatitis C
28. Tumor necrosis factor genetic polymorphisms correlate with infections after renal transplantation
29. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus genome and sensitivity of HCV to alpha interferon therapy
30. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
31. Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes
32. Long term response to interferon alpha is unrelated to interferon sensitivity determining region variability in patients with chronic hepatitis C virus 1b infection
33. Anergic T cells as active regulators of the immune response
34. Host factors in chronic viral hepatitis
35. Reduced plasma transforming growth factor levels in patients with chronic hepatitis C after interferon-α therapy: Association with regression of hepatic fibrosis
36. Cytokine gene polymorphism and heart transplant rejection
37. Immunohistochemical analysis of hepatic interferon alphabeta receptor level: Relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C
38. Late acute rejection is more prevalent among African American renal allograft recipients and is frequently associated with allograft loss